Biotech News

TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026

TG Therapeutics (TGTX)TG TherapeuticsClinical readout

Seven-year BRIUMVI data demonstrate sustained disease control, with approximately 88% of participants remaining free from confirmed disability progression after 7 years of continuous treatment Phase 1 subcutaneous BRIUMVI bioavailability data support quarterly dosing schedule being evaluated in a

Related news

TG Therapeutics

B-Cell-Directed Therapies TG Therapeutics develops and commercializes therapies targeting B cells in multiple sclerosis and other autoimmune diseases. Its portfolio combines an approved anti-CD20 antibody with alternative formulations and an allogeneic cell-therapy program. BRIUMVI BRIUMVI, or ublituximab, is a glycoengineered CD20...

Recent company news

Stock data

Close
64.88 USD
Market cap
5.61B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States